Purchase this article with an account.
T. A. Larson, S. J. Bakri, C. A. McCannel, J. S. Pulido, A. O. Edwards, D. M. Robertson; The Effect of Ranibizumab (Lucentis) on Intraocular Pressure. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1896.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the incidence of intraocular pressure (IOP) increase in patients receiving ranibizumab.
This is a retrospective chart review of 210 patients receiving 716 intravitreal injections of ranibizumab from July 2006 - July 2007.
IOP rose > 21 mmHg in 1.2% (n=9) of patients, and > 30 mmHg in 0.5% (n=1). Patients received an average of 3.4 injections over 7.6 months. Maximum IOP was 39 mmHg after 9 injections. In IOP responders, 44% had a history of glaucoma or ocular hypertension. There was no significant difference between preinjection (14 mmHg) and final postinjection IOP (14.3 mmHg) (p=0.44).
There is a low incidence of IOP rise after ranibizumab. Patients with glaucoma or ocular hypertension may be at increased risk.
This PDF is available to Subscribers Only